Evidence map›Paper›PMID 36768847›Full record

ArticleInternational journal of molecular sciences2023

Pathway and Network Analyses Identify Growth Factor Signaling and MMP9 as Potential Mediators of Mitochondrial Dysfunction in Severe COVID-19.

Ya Wang, Klaus Schughart, Tiana Maria Pelaia, Tracy Chew, Karan Kim, Thomas Karvunidis, Ben Knippenberg, Sally Teoh, Amy L Phu, Kirsty R Short and 9 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Targeting PRMT7-mediated monomethylation of MAVS enhances antiviral innate immune responses and inhibits RNA virus replication.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ya WangDepartment of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW 2747, Australia.ORCID 0000-0002-0297-8227
Klaus SchughartDepartment of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-6824-7523
Tiana Maria PelaiaDepartment of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW 2747, Australia.
Tracy ChewSydney Informatics Hub, Core Research Facilities, The University of Sydney, Sydney NSW 2006, Australia.ORCID 0000-0001-9529-7705
Karan KimCentre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Thomas KarvunidisMedical ICU, 1st Department of Internal Medicine, Charles University and Teaching Hospital Pilsen, 323 00 Plzeň, Czech Republic.
Ben KnippenbergDepartment of Microbiology, St. George Hospital, Sydney, NSW 2217, Australia.
Sally TeohDepartment of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW 2747, Australia.
Amy L PhuResearch and Education Network, Western Sydney Local Health District, Westmead Hospital, CNR Darcy and Hawkesbury Roads, Sydney, NSW 2145, Australia.ORCID 0000-0002-3704-8011
Kirsty R ShortSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-4963-6184
Jonathan IredellCentre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Irani ThevarajanVictorian Infectious Disease Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3050, Australia.
Jennifer AudsleyDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
Stephen MacdonaldCentre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Royal Perth Hospital, Perth, WA 6000, Australia.ORCID 0000-0001-9921-4620
Jonathon BurchamCentre for Clinical Research in Emergency Medicine, Royal Perth Bentley Group, Perth, WA 6000, Australia.
Predict-Consortium
Benjamin TangDepartment of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW 2747, Australia.
Anthony McLeanDepartment of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW 2747, Australia.
Maryam ShojaeiDepartment of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW 2747, Australia.

Funding

Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCWEENEY, SHANNON K. · 2012 to 2021
$36.6M
Helmholtz-Association 2-U19-AI100625-06National Health and Medical Research Council 2007919National Health and Medical Research Council APPRISE AppID 1116530NIAID NIH HHS 5U19A|100625-07NIAID NIH HHS U19 AI100625Snow Medical Research Foundation Limited CT28701/G207593
6 · The paper itself

Abstract

Patients with preexisting metabolic disorders such as diabetes are at a higher risk of developing severe coronavirus disease 2019 (COVID-19). Mitochondrion, the very organelle that controls cellular metabolism, holds the key to understanding disease progression at the cellular level. Our current study aimed to understand how cellular metabolism contributes to COVID-19 outcomes. Metacore pathway enrichment analyses on differentially expressed genes (encoded by both mitochondrial and nuclear deoxyribonucleic acid (DNA)) involved in cellular metabolism, regulation of mitochondrial respiration and organization, and apoptosis, was performed on RNA sequencing (RNASeq) data from blood samples collected from healthy controls and patients with mild/moderate or severe COVID-19. Genes from the enriched pathways were analyzed by network analysis to uncover interactions among them and up- or downstream genes within each pathway. Compared to the mild/moderate COVID-19, the upregulation of a myriad of growth factor and cell cycle signaling pathways, with concomitant downregulation of interferon signaling pathways, were observed in the severe group. Matrix metallopeptidase 9 (

Indexed as

COVID-19HumansIntercellular Signaling Peptides and ProteinsMatrix Metalloproteinase 9MitochondriaSignal TransductionIntercellular Signaling Peptides and ProteinsMatrix Metalloproteinase 9MMP9 protein, humanCOVID-19DEGendocrinemetabolismMetacoreMMP9RNA sequencing

Identifiers

PMID36768847
PMCPMC9917147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.